申联生物
(688098)
| 流通市值：22.05亿 | | | 总市值：22.05亿 |
| 流通股本：4.11亿 | | | 总股本：4.11亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 248,302,819.25 | 126,375,941.3 | 88,058,162.67 | 301,487,059.64 |
| 营业收入 | 248,302,819.25 | 126,375,941.3 | 88,058,162.67 | 301,487,059.64 |
| 二、营业总成本 | 259,262,501.74 | 162,802,956.75 | 89,817,686.58 | 270,660,170.19 |
| 营业成本 | 96,550,396.54 | 52,574,910.4 | 34,322,284.98 | 87,934,043.33 |
| 税金及附加 | 3,321,252.96 | 2,069,219.01 | 1,109,000.7 | 4,411,521.45 |
| 销售费用 | 77,225,498.63 | 53,355,521.59 | 25,474,086.12 | 84,385,612.81 |
| 管理费用 | 44,995,343.8 | 29,561,924.64 | 16,372,116.77 | 50,330,070.77 |
| 研发费用 | 37,754,809.62 | 25,619,335.99 | 12,646,826.27 | 44,527,361.94 |
| 财务费用 | -584,799.81 | -377,954.88 | -106,628.26 | -928,440.11 |
| 其中:利息收入 | 616,342.74 | 396,195.42 | 117,223.57 | 984,980.91 |
| 加:公允价值变动收益 | -35,982.52 | 116,132.31 | 16,870.39 | 2,351,924.13 |
| 加:投资收益 | 1,418,148.9 | 1,006,922.34 | 569,785.33 | 3,436,088.97 |
| 资产处置收益 | - | - | - | 482.96 |
| 资产减值损失(新) | -18,409.77 | -26,623.65 | -61,074.23 | 40,063.37 |
| 信用减值损失(新) | -12,215,863.03 | -3,729,953.73 | -2,608,986.75 | -3,131,701.04 |
| 其他收益 | 2,848,837.55 | 2,180,605.16 | 347,608.51 | 2,595,047.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -18,962,951.36 | -36,879,933.02 | -3,495,320.66 | 36,118,795.5 |
| 加:营业外收入 | 66,882.31 | 14,113.06 | - | 761,323.64 |
| 减:营业外支出 | 309,101.48 | 284,972.31 | 7,129.16 | 615,021.09 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -19,205,170.53 | -37,150,792.27 | -3,502,449.82 | 36,265,098.05 |
| 减:所得税费用 | -2,184,727.05 | -715,176.24 | -377,061.23 | 6,414,664.15 |
| 六、净利润 | -17,020,443.48 | -36,435,616.03 | -3,125,388.59 | 29,850,433.9 |
| 持续经营净利润 | -17,020,443.48 | -36,435,616.03 | -3,125,388.59 | 29,850,433.9 |
| 归属于母公司股东的净利润 | -14,124,681.4 | -34,507,973.32 | -2,209,184.73 | 31,518,678.43 |
| 少数股东损益 | -2,895,762.08 | -1,927,642.71 | -916,203.86 | -1,668,244.53 |
| (一)基本每股收益 | -0.03 | -0.08 | -0.01 | 0.08 |
| (二)稀释每股收益 | -0.03 | -0.08 | -0.01 | 0.08 |
| 九、综合收益总额 | -17,020,443.48 | -36,435,616.03 | -3,125,388.59 | 29,850,433.9 |
| 归属于母公司股东的综合收益总额 | -14,124,681.4 | -34,507,973.32 | -2,209,184.73 | 31,518,678.43 |
| 归属于少数股东的综合收益总额 | -2,895,762.08 | -1,927,642.71 | -916,203.86 | -1,668,244.53 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |